Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE
Most relevant news about JOHNSON & JOHNSON
02:33pJOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. FDA Seeking App..
PU
09/18PFIZER : Drug Companies Cheating Countries Out of Billions in Tax Revenues
AQ
09/18MCKESSON : Board of Directors Elects Dominic Caruso as New Independent Director
AQ
09/18Exclusive - India, U.S. closing in on package deal to remove trade irritants
RE
09/17JOHNSON & JOHNSON : MorphoSys Announces that its Licensee Janssen has Reported T..
AQ
09/17JOHNSON & JOHNSON : European Commission expands labelling for Janssen's INVOKANA..
AQ
09/16JOHNSON & JOHNSON : Murphy places a big bet on small pharma
AQ
09/14MANAGEMENT TRACKS : Real Endpoints, Poxel, Travecta
AQ
09/13JOHNSON & JOHNSON : washington, a. eugene
PU
09/13JOHNSON & JOHNSON : williams, ronald a
PU
09/13JOHNSON & JOHNSON : European Commission expands labelling for Janssen’s IN..
PU
09/13JOHNSON & JOHNSON : Janssen Pharmaceutical - Health-Related Quality of Life Main..
AQ
09/12JOHNSON & JOHNSON : Janssen Recognizes World Suicide Prevention Day with New Vid..
AQ
09/12With clear regulatory path, Endocyte raises $175M
AQ
09/11JOHNSON & JOHNSON : kapusta, ronald a
PU
More most relevant news
All news about JOHNSON & JOHNSON
02:33pJOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. FDA Seeking App..
PU
09:34aPFIZER : Drug companies cheating countries out of billions in tax revenues, reve..
AQ
09/18JOHNSON & JOHNSON : Expert panel holds first meeting to decide compensation for ..
AQ
09/18PFIZER : Drug Companies Cheating Countries Out of Billions in Tax Revenues
AQ
09/18JOHNSON & JOHNSON : Abbott, Johnson & Johnson, Merck, and Pfizer Depriving Count..
AQ
09/18PFIZER : Drug Companies Cheating Countries Out of Billions in Tax Revenues
AQ
09/18MCKESSON : Board of Directors Elects Dominic Caruso as New Independent Director
AQ
09/18PFIZER : Drug companies cheating New Zealand out of millions in tax revenue
AQ
09/18Exclusive - India, U.S. closing in on package deal to remove trade irritants
RE
09/17JOHNSON & JOHNSON : MorphoSys Announces that its Licensee Janssen has Reported T..
AQ
More news
Sector news : Pharmaceuticals - NEC
02:13pGerman chemical industry warns against disruptive no-deal Brexit
RE
02:12pNOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
01:44pGILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
08:15aSHIRE : Rule 2.9 Announcement
DJ
08:03aAstraZeneca plots China robot offensive to counter price cuts
RE
07:08aAstraZeneca plots China robot offensive to counter price cuts
RE
More sector news : Pharmaceuticals - NEC
Official Publications
09/11Report 
08/28Report 
07/20Report 
07/17Slide show half-year results 
07/17Half-year results 
07/16Dividends 
More Official Publications
News from SeekingAlpha
08:00aSurviving The Geron Roller Coaster As An Investor 
09/18J&J files U.S. marketing application for erdafitinib for urothelial cancer 
09/183 Reasons Most People Can't Retire 
09/18YOUR CANCER HIGHLIGHT : AbbVie Quietly Aims For A New Best-In-Class Approval In .. 
09/18Senate passes opioid crisis bill 
09/18'Mr. Valuation' Knows His Stuff, But Is 'Overvaluation' Always A Dirty Word? 
Qtime:1
Financials ($)
Sales 2018 81 257 M
EBIT 2018 24 952 M
Net income 2018 16 036 M
Debt 2018 11 280 M
Yield 2018 2,54%
P/E ratio 2018 20,75
P/E ratio 2019 17,95
EV / Sales 2018 4,78x
EV / Sales 2019 4,54x
Capitalization 377 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 144 $
Spread / Average Target 2,1%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON0.59%375 479
PFIZER18.75%252 129
NOVARTIS-1.14%215 800
ROCHE HOLDING LTD.-4.00%212 015
MERCK AND COMPANY25.15%187 284
AMGEN16.35%129 979